The Phase 3 CLEAR Trial: Lenvatinib Plus Pembrolizumab or Everolimus for Advanced RCC

home / investigator-perspectives / the-phase-3-clear-trial-lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-rcc

Recommendations for treating advanced renal cell carcinoma with the combination of lenvatinib plus pembrolizumab or lenvatinib plus everolimus, as suggested by Moshe Ornstein, MD.

Expert on RCC

EP. 1: Frontline Therapy Options for Advanced RCC and Combining IO and TKI in the First-line Setting in mRCC

Moshe C. Ornstein, MD, MA
March 18th 2022

A summary of frontline treatment options for metastatic renal cell carcinoma and the rationale for the combination of lenvatinib plus pembrolizumab.

Watch

Expert on RCC

EP. 2: Design and Key Takeaways of the CLEAR Study in Metastatic RCC

Moshe C. Ornstein, MD, MA
March 18th 2022

Results of the efficacy and safety data demonstrated by the CLEAR study of lenvatinib plus pembrolizumab or everolimus as first-line treatment for metastatic renal cell carcinoma.

Watch

Expert on RCC

EP. 3: Dosing Considerations for lenvatinib plus pembrolizumab in mRCC

Moshe C. Ornstein, MD, MA
March 18th 2022

Dr Moshe Ornstein examines dosing considerations for the combination of lenvatinib plus pembrolizumab in clinical practice and how that compares with the findings from the CLEAR study.

Watch

Expert on RCC

EP. 4: Implications of the CLEAR study in mRCC to Clinical Practice

Moshe C. Ornstein, MD, MA
March 18th 2022

Implications for treating patients with metastatic renal cell carcinoma with frontline lenvatinib plus pembrolizumab based on the regimen’s performance in the CLEAR study compared with other treatment options.

Watch

Expert on RCC

EP. 5: Subgroup Analyses of the CLEAR study in mRCC

Moshe C. Ornstein, MD, MA
March 18th 2022

An overview of data demonstrated by other investigational studies of lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma.

Watch

Expert on RCC

EP. 6: Future Direction for Patients With mRCC

Moshe C. Ornstein, MD, MA
March 18th 2022

Discussing future needs and investigating novel therapies for newly diagnosed metastatic renal cell carcinoma.

Watch